Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction

Journal of the American College of Cardiology

Volumn 74, Issue 3, 2019, Pages 299-311

  Ammirati, Enrico ^a   Veronese, Giacomo ^a,b   Brambatti, Michela ^c   Merlo, M ^d   Cipriani, Manlio ^a   Potena, Luciano ^e   Sormani, P ^a   Aoki, Tatsuo ^f   Sugimura, Koichiro ^f   Sawamura, Akinori ^g   Okumura, Takahiro ^g   Pinney, Sean ^h   Hong, Kimberly ^c   Shah, P ⁱ   Braun, Öscar ^j   Van de Heyning, Caroline M ^k   Montero, Santiago ^l,m   Petrella, Duccio ^a   Huang, Florent ^m   Schmidt, Matthieu ^m   Raineri, Claudia ⁿ   Lala, Anuradha ^h   Varrenti, Marisa ^a,b   Foà, Alberto ^e   Leone, Ornella ^e   Gentile, P ^d   Artico, Jessica ^d   Agostini, Valentina ^e   Patel, R ⁱ   Garascia, Andrea ^a   Van Craenenbroeck, Emeline M ^k   Hirose, K ^o   Isotani, Akihiro ^o   Murohara, Toyoaki ^g   Arita, Yoh ^p   Sionis, Alessandro ^l   Fabris, Enrico ^d   Hashem, Sherin ^q   Garcia Hernando, Victor ^l   Oliva, Fabrizio ^a   Greenberg, B ^c   Shimokawa, Hiroaki ^f   Sinagra, Gianfranco ^d   Adler, Eric D ^c   Frigerio, M ^a   Camici, Paolo G ^r   more..

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF TRIESTE   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ INOVA HEART AND VASCULAR INSTITUTE   (United States)

^j LUND UNIVERSITY   (Sweden)

^k ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^l HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^m SORBONNE UNIVERSITÉ   (France)

ⁿ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^o KOKURA MEMORIAL HOSPITAL   (Japan)

^p OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

acute myocarditis; endomyocardial biopsy; eosinophilic myocarditis; fulminant myocarditis; giant cell myocarditis; outcome

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE REGISTRY; EOSINOPHILIC MYOCARDITIS; EUROPE; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; FULMINANT MYOCARDITIS; GIANT CELL MYOCARDITIS; HEART DEATH; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; JAPAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LONG TERM CARE; LYMPHOCYTIC MYOCARDITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDITIS; NONFULMINANT MYOCARDITIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SOCIAL STRATIFICATION; TERTIARY CARE CENTER; TREATMENT OUTCOME; UNITED STATES; ACUTE DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; HEART LEFT VENTRICLE FUNCTION; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDITIS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85068254694     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.04.063     Document Type: Article

References (32)

1. Cooper, L.T. Jr., Myocarditis. N Engl J Med 360 (2009), 1526–1538.
2. Caforio, A.L., Pankuweit, S., Arbustini, E., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J, 34, 2013 2636–48a–d.
3. Brambatti, M., Matassini, M.V., Adler, E.D., Klingel, K., Camici, P.G., Ammirati, E., Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol 70 (2017), 2363–2375.
4. Johnson, D.B., Balko, J.M., Compton, M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
5. Postow, M.A., Sidlow, R., Hellmann, M.D., Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378 (2018), 158–168.
6. Mahmood, S.S., Fradley, M.G., Cohen, J.V., et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 (2018), 1755–1764.
7. Cooper, L.T., Baughman, K.L., Feldman, A.M., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50 (2007), 1914–1931.
8. Chow, L.H., Radio, S.J., Sears, T.D., McManus, B.M., Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 14 (1989), 915–920.
9. Aretz, H.T., Myocarditis: the Dallas criteria. Hum Pathol 18 (1987), 619–624.
10. Trachtenberg, B.H., Hare, J.M., Inflammatory cardiomyopathic syndromes. Circ Res 121 (2017), 803–818.
11. Baughman, K.L., Diagnosis of myocarditis: death of Dallas criteria. Circulation 113 (2006), 593–595.
12. Ammirati, E., Cipriani, M., Moro, C., et al., for the Registro Lombardo delle Miocarditi. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis. Circulation 138 (2018), 1088–1099.
13. Caforio, A.L., Calabrese, F., Angelini, A., et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 28 (2007), 1326–1333.
14. Kindermann, I., Kindermann, M., Kandolf, R., et al. Predictors of outcome in patients with suspected myocarditis. Circulation 118 (2008), 639–648.
15. McCarthy, R.E. 3rd, Boehmer, J.P., Hruban, R.H., et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342 (2000), 690–695.
16. Ginsberg, F., Parrillo, J.E., Fulminant myocarditis. Critic Care Clin 29 (2013), 465–483.
17. Ammirati, E., Cipriani, M., Lilliu, M., et al. Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. Circulation 136 (2017), 529–545.
18. Cooper, L.T. Jr., When lightning strikes: fulminant myocarditis in the realm of inflammatory cardiomyopathies. Circulation 136 (2017), 546–548.
19. Ammirati, E., Veronese, G., Cipriani, M., et al. Acute and fulminant myocarditis: a pragmatic clinical approach to diagnosis and treatment. Curr Cardiol Rep, 20, 2018, 114.
20. Singh, V., Mendirichaga, R., Savani, G.T., et al. Comparison of utilization trends, indications, and complications of endomyocardial biopsy in native versus donor hearts (from the Nationwide Inpatient Sample 2002 to 2014). Am J Cardiol 121 (2018), 356–363.
21. Cooper, L.T. Jr., Hare, J.M., Tazelaar, H.D., et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 102 (2008), 1535–1539.
22. Kandolin, R., Lehtonen, J., Salmenkivi, K., Raisanen-Sokolowski, A., Lommi, J., Kupari, M., Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 6 (2013), 15–22.
23. Ammirati, E., Oliva, F., Belli, O., et al. Giant cell myocarditis successfully treated with antithymocyte globuline and extracorporeal membrane oxygenation for 21 days. J Cardiovasc Med (Hagerstown) 17 Suppl 2 (2016), e151–e153.
24. Cooper, L.T. Jr., Berry, G.J., Shabetai, R., Multicenter Giant Cell Myocarditis Study Group Investigators. Idiopathic giant-cell myocarditis—natural history and treatment. N Engl J Med 336 (1997), 1860–1866.
25. Mason, J.W., O'Connell, J.B., Herskowitz, A., et al., for the Myocarditis Treatment Trial Investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 333 (1995), 269–275.
26. Asaumi, Y., Yasuda, S., Morii, I., et al. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J 26 (2005), 2185–2192.
27. Magnani, J.W., Danik, H.J., Dec, G.W. Jr., DiSalvo, T.G., Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J 151 (2006), 463–470.
28. Montero, S., Aissaoui, N., Tadié, J.-M., et al. Fulminant giant-cell myocarditis on mechanical circulatory support: management and outcomes of a French multicentre cohort. Int J Cardiol 253 (2018), 105–112.
29. Ekstrom, K., Lehtonen, J., Kandolin, R., Raisanen-Sokolowski, A., Salmenkivi, K., Kupari, M., Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail 18 (2016), 1452–1458.
30. Ukena, C., Mahfoud, F., Kindermann, I., Kandolf, R., Kindermann, M., Bohm, M., Prognostic electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart Fail 13 (2011), 398–405.
31. Sawamura, A., Okumura, T., Ito, M., et al., for the CHANGE PUMP Investigators. Prognostic value of electrocardiography in patients with fulminant myocarditis supported by percutaneous venoarterial extracorporeal membrane oxygenation: analysis from the CHANGE PUMP Study. Circ J 82 (2018), 2089–2095.
32. Frustaci, A., Russo, M.A., Chimenti, C., Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30 (2009), 1995–2002.